177 E COLORADO BLVD, PASADENA, CA
Investor Presentation
Files Complaint for Declaratory Judgment Against Pharmaceuticals, Investor Presentation
Reports Fiscal 2025 Third Quarter Results
Reports Fiscal 2025 Second Quarter Results
Appoints Daniel Apel as Chief Financial Officer
Reports Fiscal 2025 First Quarter Results
News
Annual Report to Security Holders
Amended Annual Report
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 424(b)(7)